title: Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
abstract: OBJECTIVE
  To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.
  
  
  METHODS
  Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.
  
  
  RESULTS
  In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects.
  
  
  CONCLUSIONS
  Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.
authors.affiliation: VA Connecticut Healthcare System, West Haven, CT, USA.
authors.forename: Douglas L
authors.initials: DL
authors.lastname: Boggs
authors.forename: Deanna L
authors.initials: DL
authors.lastname: Kelly
authors.forename: Robert P
authors.initials: RP
authors.lastname: McMahon
authors.forename: James M
authors.initials: JM
authors.lastname: Gold
authors.forename: David A
authors.initials: DA
authors.lastname: Gorelick
authors.forename: Jared
authors.initials: J
authors.lastname: Linthicum
authors.forename: Robert R
authors.initials: RR
authors.lastname: Conley
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.forename: James
authors.initials: J
authors.lastname: Waltz
authors.forename: Marilyn A
authors.initials: MA
authors.lastname: Huestis
authors.forename: Robert W
authors.initials: RW
authors.lastname: Buchanan
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D063387:Cannabinoid Receptor Antagonists; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D003863:Depression / Q000188:drug therapy / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010880:Piperidines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011720:Pyrazoles / Q000627:therapeutic use*; D000077285:Rimonabant; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant